BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Genmab, Seattle Genetics deal

Seattle Genetics granted Genmab rights to use its antibody-drug conjugate (ADC) technology with Genmab's preclinical cancer candidate HuMax-CD74-ADC, an ADC against CD74 molecule major histocompatibility complex class II invariant chain. Genmab is responsible...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >